46 related articles for article (PubMed ID: 20151979)
1. Targeting SYK kinase-dependent anti-apoptotic resistance pathway in B-lineage acute lymphoblastic leukaemia (ALL) cells with a potent SYK inhibitory pentapeptide mimic.
Uckun FM; Ek RO; Jan ST; Chen CL; Qazi S
Br J Haematol; 2010 May; 149(4):508-17. PubMed ID: 20151979
[TBL] [Abstract][Full Text] [Related]
2. Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia.
Chen Z; Shojaee S; Buchner M; Geng H; Lee JW; Klemm L; Titz B; Graeber TG; Park E; Tan YX; Satterthwaite A; Paietta E; Hunger SP; Willman CL; Melnick A; Loh ML; Jung JU; Coligan JE; Bolland S; Mak TW; Limnander A; Jumaa H; Reth M; Weiss A; Lowell CA; Müschen M
Nature; 2015 May; 521(7552):357-61. PubMed ID: 25799995
[TBL] [Abstract][Full Text] [Related]
3. Identification and targeting of CD22ΔE12 as a molecular RNAi target to overcome drug resistance in high-risk B-lineage leukemias and lymphomas.
Uckun FM; Qazi S
Cancer Drug Resist; 2018; 1():30-47. PubMed ID: 31788667
[TBL] [Abstract][Full Text] [Related]
4. Repurposing anthelmintic agents to eradicate resistant leukemia.
Mezzatesta C; Abduli L; Guinot A; Eckert C; Schewe D; Zaliova M; Vinti L; Marovca B; Tsai YC; Jenni S; Aguade-Gorgorio J; von Stackelberg A; Schrappe M; Locatelli F; Stanulla M; Cario G; Bourquin JP; Bornhauser BC
Blood Cancer J; 2020 Jun; 10(6):72. PubMed ID: 32591499
[TBL] [Abstract][Full Text] [Related]
5. Cell surface GRP78: a potential mechanism of therapeutic resistant tumors.
Amaresan R; Gopal U
Cancer Cell Int; 2023 May; 23(1):100. PubMed ID: 37221596
[TBL] [Abstract][Full Text] [Related]
6. Tyrosine kinases in KMT2A/MLL-rearranged acute leukemias as potential therapeutic targets to overcome cancer drug resistance.
Uckun FM; Qazi S
Cancer Drug Resist; 2022; 5(4):902-916. PubMed ID: 36627892
[No Abstract] [Full Text] [Related]
7. Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition.
Köhrer S; Havranek O; Seyfried F; Hurtz C; Coffey GP; Kim E; Ten Hacken E; Jäger U; Vanura K; O'Brien S; Thomas DA; Kantarjian H; Ghosh D; Wang Z; Zhang M; Ma W; Jumaa H; Debatin KM; Müschen M; Meyer LH; Davis RE; Burger JA
Leukemia; 2016 Jun; 30(6):1246-54. PubMed ID: 26847027
[TBL] [Abstract][Full Text] [Related]
8. Liposomal Nanoparticles of a Spleen Tyrosine Kinase P-Site Inhibitor Amplify the Potency of Low Dose Total Body Irradiation Against Aggressive B-Precursor Leukemia and Yield Superior Survival Outcomes in Mice.
Uckun FM; Myers DE; Cheng J; Qazi S
EBioMedicine; 2015 Jun; 2(6):554-62. PubMed ID: 26285772
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules.
Yu Y; Gaillard S; Phillip JM; Huang TC; Pinto SM; Tessarollo NG; Zhang Z; Pandey A; Wirtz D; Ayhan A; Davidson B; Wang TL; Shih IeM
Cancer Cell; 2015 Jul; 28(1):82-96. PubMed ID: 26096845
[TBL] [Abstract][Full Text] [Related]
10. Calling in SYK: SYK's dual role as a tumor promoter and tumor suppressor in cancer.
Krisenko MO; Geahlen RL
Biochim Biophys Acta; 2015 Jan; 1853(1):254-63. PubMed ID: 25447675
[TBL] [Abstract][Full Text] [Related]
11. Nanopharmacology in translational hematology and oncology.
Tomuleasa C; Braicu C; Irimie A; Craciun L; Berindan-Neagoe I
Int J Nanomedicine; 2014; 9():3465-79. PubMed ID: 25092977
[TBL] [Abstract][Full Text] [Related]
12. Syk interacts with and phosphorylates nucleolin to stabilize Bcl-x(L) mRNA and promote cell survival.
Wang WH; Childress MO; Geahlen RL
Mol Cell Biol; 2014 Oct; 34(20):3788-99. PubMed ID: 25092868
[TBL] [Abstract][Full Text] [Related]
13. CD19-antigen specific nanoscale liposomal formulation of a SYK P-site inhibitor causes apoptotic destruction of human B-precursor leukemia cells.
Myers DE; Yiv S; Qazi S; Ma H; Cely I; Shahidzadeh A; Arellano M; Finestone E; Gaynon PS; Termuhlen A; Cheng J; Uckun FM
Integr Biol (Camb); 2014 Aug; 6(8):766-80. PubMed ID: 24910947
[TBL] [Abstract][Full Text] [Related]
14. SYK as a New Therapeutic Target in B-Cell Precursor Acute Lymphoblastic Leukemia.
Uckun FM; Qazi S
J Cancer Ther; 2014 Jan; 5(1):124-131. PubMed ID: 24851191
[TBL] [Abstract][Full Text] [Related]
15. Targeting Mantle Cell Lymphoma with Anti-SYK Nanoparticles.
Cely I; Yiv S; Yin Q; Shahidzadeh A; Tang L; Cheng J; Uckun FM
J Anal Oncol; 2012 Jun; 1(1):1-9. PubMed ID: 23730399
[TBL] [Abstract][Full Text] [Related]
16. Nanoscale liposomal formulation of a SYK P-site inhibitor against B-precursor leukemia.
Uckun FM; Qazi S; Cely I; Sahin K; Shahidzadeh A; Ozercan I; Yin Q; Gaynon P; Termuhlen A; Cheng J; Yiv S
Blood; 2013 May; 121(21):4348-54. PubMed ID: 23568490
[TBL] [Abstract][Full Text] [Related]
17. Pediatric relapsed or refractory leukemia: new pharmacotherapeutic developments and future directions.
August KJ; Narendran A; Neville KA
Drugs; 2013 Apr; 73(5):439-61. PubMed ID: 23568274
[TBL] [Abstract][Full Text] [Related]
18. Protein kinase inhibitors against malignant lymphoma.
D'Cruz OJ; Uckun FM
Expert Opin Pharmacother; 2013 Apr; 14(6):707-21. PubMed ID: 23496343
[TBL] [Abstract][Full Text] [Related]
19. Syk activation of phosphatidylinositol 3-kinase/Akt prevents HtrA2-dependent loss of X-linked inhibitor of apoptosis protein (XIAP) to promote survival of Epstein-Barr virus+ (EBV+) B cell lymphomas.
Hatton O; Phillips LK; Vaysberg M; Hurwich J; Krams SM; Martinez OM
J Biol Chem; 2011 Oct; 286(43):37368-78. PubMed ID: 21908615
[TBL] [Abstract][Full Text] [Related]
20. Cancer genomics: from discovery science to personalized medicine.
Chin L; Andersen JN; Futreal PA
Nat Med; 2011 Mar; 17(3):297-303. PubMed ID: 21383744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
